Jacobs, M S <br/><br/>
Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands.  [electronic resource] 

 -  Journal of medical economics  Dec 2017 
 - 1231-1236 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.1080/13696998.2017.1363766  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acenocoumarol--adverse effects<br/>Aged<br/>Aged, 80 and over<br/>Anticoagulants--adverse effects<br/>Atrial Fibrillation--drug therapy<br/>Cardiology--economics<br/>Dabigatran--adverse effects<br/>Embolism--economics<br/>Female<br/>Hemorrhage--chemically induced<br/>Hospital Charges--statistics & numerical data<br/>Humans<br/>Male<br/>Middle Aged<br/>Netherlands<br/>Propensity Score<br/>Retrospective Studies<br/>Sex Factors<br/>Stroke--economics